Skip to content

Gasless Single-port Laparoscopic-assisted Radical Resection for Rectal Carcinoma

Efficacy and Safety of Gasless Single-port Laparoscopic-assisted Radical Resection for Rectal Carcinoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03318185
Enrollment
200
Registered
2017-10-23
Start date
2017-11-01
Completion date
2020-09-01
Last updated
2018-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Surgery

Keywords

gasless single-port laparoscopic surgery;rectal carcinoma

Brief summary

This project aims to investigate the safety and effectiveness of gasless single-port laparoscopic-assisted radical resection (GSLR) in the treatment of rectal carcinoma.

Detailed description

The gasless single-port laparoscopic-assisted surgery (GSLS) is associated with rapid recovery and shorter postoperative hospital stay and no pneumoperitoneum complications occur after the operation. To our knowledge, there have been no reports about GSLS applied to the treatment of gastrointestinal cancer in the world. To explore the safety and effectiveness of GSLS in rectal cancer patients, this project plans to evaluate the operation time, cardio-pulmonary function, postoperative pain, immunologic function and restoration of bowel function after the operation.

Interventions

PROCEDUREgasless single-port laparoscopic surgery

The single-port laparoscopic surgery is performed when the maneuvering room is provided by external suspension system.

The multi-port laparoscopic surgery is performed when the belly is inflated with carbon dioxide to provide maneuvering room.

Sponsors

The Second Affiliated Hospital of Chongqing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Rectal carcinoma;The distance between tumor and anal verge is 5-15cm; The primary tumor can radical resect.

Exclusion criteria

* Neoadjuvant therapy;Surgical contraindication.

Design outcomes

Primary

MeasureTime frameDescription
Pulmonary functionChange from baseline PaO2/FiO2 ratio 10 minutes after the surgery is over.Estimate the pulmonary function in the perioperational period by blood gas analysis, which will be compared with comparator.The main parameter partial pressure of oxygen(PaO2)/inspired oxygen fraction(FiO2) ratio is the ratio of arterial oxygen partial pressure to fractional inspired oxygen.
Immunologic functionChange from baseline CD4/CD8 ratio 7 days after operation.Estimate the immunologic function in the perioperational period by blood lymphocyte analysis, which will be compared with comparator.The main parameter cluster of differentiation 4(CD4)/cluster of differentiation 8(CD8) ratio is the ratio of lymphocyte CD4 numbers to lymphocyte CD8 numbers.

Secondary

MeasureTime frameDescription
Operation timeat 1 dayMeasure the operation time, which will be compared with comparator.
Postoperative pain72 hours after operationMeasure the postoperative pain after operation by numerical rating scale(NRS), which will be compared with comparator.
Bowel functionup to 1 week after operationMeasure the restoration of bowel function after operation, which will be compared with comparator.The bowel function was evaluated by first flatus.
Number of the lymph node dissectionat 1 week after operationMeasure the number of the regional lymph node dissection after operation, which will be compared with comparator.

Countries

China

Contacts

Primary ContactJijian Wang, phD
wangjj1963@163.com02363693511
Backup ContactJianbo Zhang, phD
172329491@qq.com02363693510

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026